Source link : https://las-vegas-news.com/fda-recalls-mg217-eczema-cream-over-staph-risk/
Eczema cream recalled over risk of ‘life-threatening’ staph infection – Image for illustrative purposes only (Image credits: Unsplash)
The Food and Drug Administration announced the recall of a widely available eczema treatment after laboratory tests revealed contamination with Staphylococcus aureus. Pharmacal, the Jackson, Wisconsin-based manufacturer, is withdrawing its MG217 Multi-symptom Treatment Cream & Skin Protectant from distribution. The action follows confirmation that the product poses a serious infection hazard to users.
Scope of the Recall
The affected cream is marketed for eczema relief and general skin protection. It was sold through retail outlets and online channels across the United States. Pharmacal initiated the voluntary recall after internal testing identified the bacterial presence in certain batches.
Distribution records show the product reached pharmacies, supermarkets, and direct-to-consumer sellers. No specific lot numbers have been released publicly yet, so regulators advise checking all units on hand. The company has halted further shipments while the investigation continues.
Potential Health Consequences
Staphylococcus aureus can trigger skin infections that range from mild irritation to deep tissue damage. In vulnerable individuals the bacteria may enter the bloodstream and produce life-threatening complications. The FDA classified the risk level as significant enough to warrant immediate removal from shelves.
People with compromised…
—-
Author : Matthias Binder
Publish date : 2026-05-13 09:02:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8